Insulin Glargine
- 1 May 2003
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Heart Disease
- Vol. 5 (3), 231-240
- https://doi.org/10.1097/01.hdx.0000074514.20750.57
Abstract
Optimal glucose control is the primary goal for treating diabetes mellitus and preventing long-term complications of diabetes, such as coronary heart disease, nephropathy, neuropathy and retinopathy. Insulin glargine is a novel, long-acting human insulin analog that is indicated in type 1 diabetic patients aged ≥6, or in type 2 diabetic patients who require basal insulin for glycemic control. Insulin glargine is a recombinant insulin with a modified structure that allows it to dissolve in an acidic solution, but to precipitate in the physiological subcutaneous tissue forming a depot effect. In contrast to Neutral Protamine Hagedorn (NPH) insulin, insulin glargine has a slower onset, a longer duration of action, and no peak in metabolic activity. Once-daily subcutaneous administration of insulin glargine at bedtime has comparable efficacy to that of NPH insulin once or twice daily when used in combination with bolus insulin in type 1 diabetic patients, or in conjunction with oral antidiabetic drugs in type 2 diabetic patients. Overall, insulin glargine has similar adverse effects when compared with NPH insulin. Insulin glargine has been associated with less nocturnal hypoglycemia and improved treatment satisfaction in several clinical trials with durations ofKeywords
This publication has 32 references indexed in Scilit:
- Treating dual defects in diabetes: insulin resistance and insulin secretion.American Journal of Health-System Pharmacy, 2002
- Insulin Strategies for Primary Care ProvidersClinical Diabetes, 2002
- Standards of Medical Care for Patients With Diabetes MellitusDiabetes Care, 2002
- INSULIN THERAPY IN TYPE 2 DIABETESEndocrinology and Metabolism Clinics of North America, 2001
- Recent advances in treatment of youth with Type 1 diabetes: better care through technologyDiabetic Medicine, 2001
- Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational studyBMJ, 2000
- Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.Diabetes Care, 2000
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projectionsDiabetes Care, 1998
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993